Applications of Pitavastatin Calcium in Industrial Manufacturing

Pitavastatin Calcium serves as a key statin-class pharmaceutical intermediate in the global statin drug industry, supporting a range of specialized finished dosage formulations. As the direct manufacturer, we supply pharmaceutical-grade material optimized for precise integration in advanced downstream processing and strict regulatory environments. Below we detail prominent industrial application scenarios, highlighting specific integration points, relevant quality standards, functional loading levels, and end product types for each segment.

1. Branded and Generic Statin Oral Tablets

The principal application for this active pharmaceutical ingredient is in the tableting of cholesterol-lowering medications, both under established brand portfolios and generic product lines. Finished manufacturers require the material to meet stringent international pharmacopoeial monographs and specification parameters for direct compression or wet granulation, as it constitutes the principal active component of the final formulation. Manufacturers formulate using validated QC protocols to ensure batch consistency, content uniformity, and processability, resulting in prescription pharmaceuticals distributed worldwide.

Industry compliance standards

• USP (United States Pharmacopeia) monograph for Pitavastatin Calcium
• EP (European Pharmacopoeia) requirements
• ICH Q7 GMP and local GMP regulations
• WHO Prequalification and local regulatory authority registrations

Typical usage ratio

• Active loading per tablet: 1 mg, 2 mg, or 4 mg (as specified by dose form strength), representing 0.5–1.5% of total tablet mass; actual ratio adjusted to target the authorized dose for the market

Downstream process integration

• Introduced during granulation stage for wet granulation, or blended directly with excipients for direct compression tablet manufacturing; passes through blending, granulation (if applicable), compression, and tablet coating processes

Final product types

• Finished film-coated tablets (1 mg, 2 mg, 4 mg doses)
• Uncoated compressed tablets for further processing
• Bulk tablets supplied to contract packaging operations

2. Solid Oral Capsules (Hard Gelatin and HPMC)

Pitavastatin Calcium is formulated by some pharmaceutical manufacturers into solid capsule dosage forms, utilizing either hard gelatin or vegetarian HPMC shells. This approach is chosen when market differentiation, stability, or specific release profiles are required. Stringent control of blend uniformity and particle size distribution ensures content uniformity in encapsulation processes designed to meet international safety and registration standards.

Industry compliance standards

• cGMP (current Good Manufacturing Practice, 21 CFR Parts 210/211)
• JP (Japanese Pharmacopoeia) for domestic Japanese finished goods
• FDA Drug Master File referencing (as required for ANDA submissions)
• Health Canada guidelines for prescription oral capsules

Typical usage ratio

• Single capsule unit contains 1–4 mg of active, usually representing 0.4–1.2% of total capsule fill weight; content level calibrated to final dosage requirements and capsule volume selection

Downstream process integration

• Active ingredient premixed with excipients in a ribbon blender, followed by encapsulation using high-speed automatic capsule filling machines; often includes in-process QC for fill weight and uniformity

Final product types

• Hard gelatin prescription statin capsules
• Vegetarian HPMC capsules for markets with dietary restrictions
• Blister-packed unit dose statin medications

3. Fixed-Dose Combination (FDC) Statin Tablets

Pharmaceutical producers use Pitavastatin Calcium as a key component in fixed-dose combination (FDC) cardiovascular tablets combining multiple actives, such as antihypertensive agents and other lipid-regulating drugs. This sector requires precision in actives’ ratio, incorporation during multi-stage granulation processes, and rigorous stability monitoring to comply with the advanced demands of polypharmacy regulatory submissions.

Industry compliance standards

• EMA (European Medicines Agency) guidelines for combination drugs
• Indian CDSCO FDC registration regulations
• ICH Stability Guidelines (Q1A-Q1E series) for FDC products
• Relevant national monographs for each active substance

Typical usage ratio

• 1–4 mg Pitavastatin Calcium per tablet, with relative actives’ mass tailored to match combination therapy targets; statin’s mass fraction typically under 3% of final FDC mass

Downstream process integration

• Introduced at specific granulation or blending stage to ensure compatibility with other APIs; monitored through high-performance liquid chromatography for content uniformity in tri-layer or multi-granule FDC tablets

Final product types

• Dual and triple fixed-dose cardiovascular tablets
• Co-formulated statin plus antihypertensive combination tablets
• Blister-packed polytherapy solid dose forms

4. Bulk API for Contract Manufacturing and Regulatory Fill-Finish Operations

Contract development and manufacturing organizations (CDMOs) and regulatory fill-finish facilities procure Pitavastatin Calcium in bulk for conversion into finished statin pharmaceuticals destined for specific markets. These operators require full traceability, regulatory support with active substance master files, and consistent material quality for integration into their validated production lines. Batch documentation, analytical documentation, and on-site GMP audits form a core aspect of this scenario.

Industry compliance standards

• EU-GMP Part II (for active substances)
• Chinese Pharmacopeia (as required for the China market)
• ISO 9001:2015 for quality management systems in pharma supply chains
• ICH Q3A/B (Impurities in New Drug Substances/Products) guidance for regulatory submissions

Typical usage ratio

• Bulk API dispensed according to finished product batch size; per-batch integration based on targeted unit-dose, typically 1–4 mg per solid unit, quantities scaled for multi-lot tableting or encapsulation campaigns

Downstream process integration

• Dispersed into granulation, direct blending, or capsule filling lines at GMP-licensed plants; supported with supplier qualification, on-site release testing, and full documentation transfer for regulatory filings

Final product types

• Branded and generic statin tablet/capsule finished dosages
• Custom-labeled solid oral forms for global pharma brands
• Bulk-packed oral statins for third-party packaging or direct distribution